Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 11/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1412845 | 0.88 | P2RX7 (0.59) | P2RX7ABCB11THRBTHRAMEN1 | |
| SCHEMBL3346080 | 0.84 | P2RX7 (0.47) | P2RX7ABCB11THRBLMNARAB9A | |
| SCHEMBL3348736 | 0.81 | P2RX7 (0.48) | P2RX7ABCB11THRBLMNASMN1; SMN2 | |
| SCHEMBL3342520 | 0.79 | P2RX7 (0.47) | P2RX7LMNARAB9ASMN1; SMN2SIRT3 | |
| SCHEMBL6169134 | 0.79 | P2RX7 (0.51) | P2RX7ABCB11THRBTHRAKMT2A | |
| SCHEMBL3346920 | 0.78 | RAB9A (0.45) | P2RX7LMNARAB9ASMN1; SMN2SIRT3 | |
| SCHEMBL3340313 | 0.78 | CRBN (0.46) | P2RX7LMNARAB9ASMN1; SMN2SIRT3 | |
| SCHEMBL30504582 | 0.78 | THRB (0.58) | P2RX7ABCB11THRBLMNASMN1; SMN2 | |
| SCHEMBL8961567 | 0.78 | THRB (0.58) | P2RX7ABCB11THRBLMNASMN1; SMN2 | |
| SCHEMBL30504581 | 0.78 | THRB (0.58) | P2RX7ABCB11THRBLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160384-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160384-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | P2RY1, P2RX6, P2RX3 | P2RX7 8/4885ABCB11 1044/4885THRB 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.